This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!
TheStreet Rating

10 Best Life Sciences Stocks for 2015

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks. These 10 life sciences stocks are rated highest by our methodology.

Equity Top: Life Sciences Tools & Services

Source: TheStreet Ratings

Best Investments for 2015

Life Sciences

Takeover candidate United Therapeutics fights Sandoz over patents for treating a rare disorder.
2/27/15 1:58PM
In trading on Friday, shares of Aegerion Pharmaceuticals Inc crossed above their 200 day moving average of $28.23, changing hands as high as $28.85 per share. Aegerion Pharmaceuticals Inc shares are currently trading off about 2.1% on the day.
2/27/15 11:48AM
Horizon Pharma (HZNP) shares are up almost double digits following the company's earnings beat and revised fiscal 2015 guidance.
2/27/15 10:31AM
BroadSoft, TG Therapeutics and Ziopharm Oncology also have room for further gains, according to a technical analysis of their recent stock activity.
2/27/15 6:30AM
Cramer says he's a fan of Monster Beverage and Ross Stores after reporting better-than-expected earnings and Clean Harbors' business remains on track as does Receptos' drug plans.
2/27/15 6:00AM
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
2/27/15 6:00AM
The most recent short interest data has been released by the NASDAQ for the 02/13/2015 settlement date, which shows a 274,894 share increase in total short interest for Foundation Medicine Inc , to 2,721,905, an increase of 11.23% since 01/30/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
2/26/15 3:45PM
The most recent short interest data has been released by the NASDAQ for the 02/13/2015 settlement date, which shows a 3,870,322 share increase in total short interest for Array BioPharma Inc. , to 23,749,847, an increase of 19.47% since 01/30/2015.
2/26/15 3:31PM
As the Nasdaq approaches the 5,000 mark, the CNBC 'Fast Money Halftime' trading panel examines whether this time is different.
2/26/15 2:30PM
A look at the weighted underlying holdings of the SPDR S&P Biotech ETF (XBI) shows an impressive 18.5% of holdings on a weighted basis have experienced insider buying within the past six months. START SLIDESHOW:10 ETFs With Stocks That Insiders Are Buying ยป Tesaro Inc , which makes up 1.37% of the SPDR S&P Biotech ETF (XBI), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data.
2/26/15 9:40AM
TheStreet highlights 3 stocks pushing the drugs industry lower today.
2/25/15 12:06PM
TheStreet highlights 3 stocks pushing the drugs industry higher today.
2/25/15 12:05PM
To buy PTC Therapeutics today would cost roughly $3 billion, a significant pile of cash to risk on an investment that could blow up at the end of the year.
2/25/15 11:47AM
Ampio Pharmaceuticals completed a clinical trial of its diabetic macular edema drug Optina in November, but it is just too busy to disclose results.
2/25/15 7:55AM
The following Pall (PLL) conference call took place on February 24, 2015, 08:30 AM ET. This is a transcript of that earnings call:
2/24/15 6:00PM

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs